At the conclusion of this activity, participants will be able to:
  • Describe the latest advances in the understanding of molecular features of tumors with ‘BRCAness’ or BRCA1/2 mutations and the rationale for the use of PARP inhibitors in these tumors.
  • Assess current and evolving data on the safety and efficacy of PARP inhibitors in ovarian cancer with BRCA1/2 and other DDR-related mutations.
  • Examine the role of recommended genetic testing and counseling in patients with possible deleterious mutations in the DNA damage response pathway and its implications on treatment decisions and patient outcomes.
  • Discuss top clinical questions and patient cases pertaining to the treatment and management of advanced ovarian cancer patients with BRCA1/2 or other DDR-related mutations.